[go: up one dir, main page]

MX2020009462A - Procesos para la preparación de compuestos de pirimidinilciclopentano. - Google Patents

Procesos para la preparación de compuestos de pirimidinilciclopentano.

Info

Publication number
MX2020009462A
MX2020009462A MX2020009462A MX2020009462A MX2020009462A MX 2020009462 A MX2020009462 A MX 2020009462A MX 2020009462 A MX2020009462 A MX 2020009462A MX 2020009462 A MX2020009462 A MX 2020009462A MX 2020009462 A MX2020009462 A MX 2020009462A
Authority
MX
Mexico
Prior art keywords
preparation
sup
flexible substrate
wearable
useful
Prior art date
Application number
MX2020009462A
Other languages
English (en)
Inventor
Michelangelo Scalone
Hans Iding
Reinhard Reents
Francis Gosselin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2020009462A publication Critical patent/MX2020009462A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/02—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from isocyanates with formation of carbamate groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C12P17/165—Heterorings having nitrogen atoms as the only ring heteroatoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención se relaciona con un proceso para la preparación de un compuesto de fórmula (I), donde R1 es como se define en la presente, que es útil como un intermediario en la preparación de los compuestos farmacéuticos activos.
MX2020009462A 2013-11-15 2014-11-13 Procesos para la preparación de compuestos de pirimidinilciclopentano. MX2020009462A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13193030 2013-11-15
PCT/US2014/065567 WO2015073739A1 (en) 2013-11-15 2014-11-13 Processes for the preparation of pyrimidinylcyclopentane compounds

Publications (1)

Publication Number Publication Date
MX2020009462A true MX2020009462A (es) 2021-08-31

Family

ID=49582648

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2020009462A MX2020009462A (es) 2013-11-15 2014-11-13 Procesos para la preparación de compuestos de pirimidinilciclopentano.
MX2016006299A MX367620B (es) 2013-11-15 2014-11-13 Procesos para la preparación de compuestos de pirimidinilciclopentano.
MX2019006959A MX374852B (es) 2013-11-15 2014-11-13 Procesos para la preparacion de compuestos de pirimidinilciclopentano

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2016006299A MX367620B (es) 2013-11-15 2014-11-13 Procesos para la preparación de compuestos de pirimidinilciclopentano.
MX2019006959A MX374852B (es) 2013-11-15 2014-11-13 Procesos para la preparacion de compuestos de pirimidinilciclopentano

Country Status (22)

Country Link
US (3) US9862689B2 (es)
EP (3) EP3068770B1 (es)
JP (4) JP6374503B2 (es)
KR (2) KR102493603B1 (es)
CN (3) CN110590606B (es)
AR (1) AR098427A1 (es)
AU (5) AU2014348570B2 (es)
CA (2) CA2930870C (es)
ES (2) ES2765511T3 (es)
HK (1) HK1223102A1 (es)
HR (2) HRP20231100T1 (es)
HU (1) HUE063095T2 (es)
IL (3) IL245636B (es)
MX (3) MX2020009462A (es)
MY (2) MY174153A (es)
NZ (1) NZ720805A (es)
PL (2) PL3068770T3 (es)
RU (1) RU2702355C1 (es)
SG (1) SG10201901578UA (es)
SI (1) SI3068770T1 (es)
WO (1) WO2015073739A1 (es)
ZA (2) ZA201603434B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020009462A (es) * 2013-11-15 2021-08-31 Hoffmann La Roche Procesos para la preparación de compuestos de pirimidinilciclopentano.
SI3197875T1 (sl) 2014-09-26 2019-12-31 F. Hoffmann-La Roche Ag Postopki za pripravo (ciklopentil(D)pirimidin-4-IL)piperazinskih spojin
KR20250023595A (ko) 2016-08-10 2025-02-18 에프. 호프만-라 로슈 아게 Akt 단백질 키나아제 저해제를 포함하는 약학 조성물
GB201802383D0 (en) * 2018-02-14 2018-03-28 Givaudan Sa Process

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6545165B1 (en) 2000-02-04 2003-04-08 Roche Colorado Corporation Synthesis of 3,6-dialkyl-5,6-dihydro-4-hydroxy-pyran-2-one
ATE407126T1 (de) * 2005-05-24 2008-09-15 Hoffmann La Roche Herstellung von (s)-4-fluormethyl-dihydro-furan-2-on
CN101198594A (zh) * 2005-06-22 2008-06-11 尼科梅德有限责任公司 用于制备生产三环苯并咪唑类的中间体的方法
UA95641C2 (xx) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
AU2007269052B2 (en) * 2006-07-06 2014-10-23 Array Biopharma Inc. Cyclopenta [D] pyrimidines as AKT protein kinase inhibitors
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
WO2009029554A2 (en) 2007-08-24 2009-03-05 Codexis, Inc. Improved ketoreductase polypeptides for the stereoselective production of (r)-3-hydroxythiolane
KR101624752B1 (ko) * 2008-01-09 2016-05-26 어레이 바이오파마 인크. Ａｋｔ 단백질 키나제 저해물질로써의 수산화된 피리미딜 시클로펜탄
CA2711699A1 (en) 2008-01-09 2009-07-16 Array Biopharma Inc. Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
PE20091364A1 (es) * 2008-01-17 2009-10-13 Novartis Ag Proceso para la preparacion de inhibidores de nep
EP2329013B1 (en) 2008-08-27 2015-10-28 Codexis, Inc. Ketoreductase polypeptides for the production of a 3-aryl-3-hydroxypropanamine from a 3-aryl-3-ketopropanamine
WO2010025085A2 (en) 2008-08-29 2010-03-04 Codexis, Inc. Ketoreductase polypeptides for the stereoselective production of (4s)-3[(5s)-5(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one
US20110054174A1 (en) * 2009-08-28 2011-03-03 Stephan Bachmann Process for the preparation of a glucokinase activator compound
EP2558864A1 (en) * 2010-04-16 2013-02-20 Genentech, Inc. Fox03a as predictive biomarker for pi3k/akt kinase pathway inhibitor efficacy
MX2013011329A (es) * 2011-04-01 2014-03-12 Genentech Inc Combinaciones de compuestos inhibidores de akt y erlotinib y metodos de uso.
SG11201407625WA (en) * 2012-05-17 2014-12-30 Genentech Inc Process for making amino acid compounds
RU2650511C2 (ru) * 2012-05-17 2018-04-16 Дженентек, Инк. Формы и составы пиримидинилциклопентанового соединения, композиции и способы, относящиеся к ним
CN104487430B (zh) 2012-05-17 2016-08-24 阵列生物制药公司 用于制造羟基化的环戊基嘧啶化合物的方法
MY169028A (en) * 2012-05-17 2019-02-04 Genentech Inc Process for making hydroxylated cyclopentylpyrimidine compounds
CA2873661C (en) * 2012-05-17 2020-07-21 Genentech, Inc. Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
MX2020009462A (es) * 2013-11-15 2021-08-31 Hoffmann La Roche Procesos para la preparación de compuestos de pirimidinilciclopentano.
SI3197875T1 (sl) 2014-09-26 2019-12-31 F. Hoffmann-La Roche Ag Postopki za pripravo (ciklopentil(D)pirimidin-4-IL)piperazinskih spojin

Also Published As

Publication number Publication date
JP6374503B2 (ja) 2018-08-15
US10435378B2 (en) 2019-10-08
US20180086722A1 (en) 2018-03-29
IL271331B (en) 2021-03-25
JP6634428B2 (ja) 2020-01-22
IL281072B (en) 2022-05-01
US20160297773A1 (en) 2016-10-13
CN110590606B (zh) 2023-02-17
NZ720805A (en) 2022-01-28
CA2930870A1 (en) 2015-05-21
AR098427A1 (es) 2016-05-26
KR20220139440A (ko) 2022-10-14
EP4282973A3 (en) 2024-03-27
CA2930870C (en) 2023-09-19
MY191759A (en) 2022-07-14
MY174153A (en) 2020-03-11
JP2016539939A (ja) 2016-12-22
CN105899492A (zh) 2016-08-24
AU2014348570A1 (en) 2016-06-09
JP2018052966A (ja) 2018-04-05
MX2016006299A (es) 2017-02-22
CN112898210A (zh) 2021-06-04
EP4282973A2 (en) 2023-11-29
EP3656764C0 (en) 2023-07-05
AU2014348570B2 (en) 2019-02-28
MX374852B (es) 2025-03-06
RU2702355C1 (ru) 2019-10-08
SG10201901578UA (en) 2019-03-28
MX367620B (es) 2019-08-28
CN110590606A (zh) 2019-12-20
EP3068770A1 (en) 2016-09-21
HUE063095T2 (hu) 2023-12-28
IL271331A (en) 2020-01-30
SI3068770T1 (sl) 2020-02-28
ES2765511T3 (es) 2020-06-09
AU2019202461B2 (en) 2021-01-14
MX2019006959A (es) 2019-08-01
KR102698200B1 (ko) 2024-08-26
CN105899492B (zh) 2021-08-24
HK1223102A1 (zh) 2017-07-21
AU2022275477A1 (en) 2023-01-05
US9862689B2 (en) 2018-01-09
CA3207199A1 (en) 2015-05-21
PL3068770T3 (pl) 2020-04-30
HRP20231100T1 (hr) 2023-12-22
JP2019218384A (ja) 2019-12-26
KR102493603B1 (ko) 2023-01-31
US20200062717A1 (en) 2020-02-27
WO2015073739A1 (en) 2015-05-21
BR112016011048A2 (pt) 2017-08-08
IL245636B (en) 2019-12-31
EP3656764A1 (en) 2020-05-27
RU2019130505A (ru) 2020-02-18
US10858324B2 (en) 2020-12-08
ZA201603434B (en) 2020-08-26
IL245636A0 (en) 2016-06-30
JP2021100953A (ja) 2021-07-08
ZA202002611B (en) 2023-10-25
JP7377828B2 (ja) 2023-11-10
PL3656764T3 (pl) 2024-01-22
KR20160075816A (ko) 2016-06-29
AU2019202461A1 (en) 2019-05-02
HRP20192340T1 (hr) 2020-04-03
EP3068770B1 (en) 2019-10-23
IL281072A (en) 2021-04-29
AU2021202196A1 (en) 2021-05-06
JP6857219B2 (ja) 2021-04-14
BR112016011048A8 (pt) 2020-04-22
ES2957314T3 (es) 2024-01-17
EP3656764B1 (en) 2023-07-05
RU2016123365A (ru) 2017-12-18
EP3068770A4 (en) 2017-04-19
CN112898210B (zh) 2025-02-21
AU2024205845A1 (en) 2024-09-05

Similar Documents

Publication Publication Date Title
WO2014052506A3 (en) Facilitating affective feedback using wearable computing devices
WO2015108601A3 (en) Vibration energy compensation for a skin surface microphone ("ssm") in wearable communication devices
MX374852B (es) Procesos para la preparacion de compuestos de pirimidinilciclopentano
PH12015501082B1 (en) Pyridine -2-amides useful as cb2 agonists
MY193578A (en) Camera module and mobile terminal
EP4202959A3 (en) Overvoltage protection devices including wafer of varistor material
NZ715920A (en) Pesticidal compositions and processes related thereto
MX382178B (es) Dispositivo sostenible con una mano para tratamiento dermico accionado electricamente
MX2021007988A (es) Sistema, metodo y aparato para el cuidado electronico de pacientes.
BR112015005078A2 (pt) chapa com elemento de conexão elétrica
TWD166671S (zh) 電纜連接器之引線框外殼及電接觸件
BR112014016136A2 (pt) estruturas de pacote incluindo antenas distintas montadas em um dispositivo
WO2014195482A3 (en) Organic electronic device
MA33937B1 (fr) Composes pyrazole comme antagonistes du recepteur crth2
WO2011103952A8 (en) Electrode treatment process for organic electronic devices
WO2013117588A3 (en) A thin film for a lead for brain applications
DE102018214362B8 (de) Direkt am gerät zu montierender abschirmverbinder
EP2645498A3 (en) Electrical system enclosures
NZ711191A (en) Benzo-fused heterocyclic derivatives useful as agonists of gpr120
GB201008492D0 (en) An antenna
BR112015030249A2 (pt) eletrodo médico, e garra de membro para um dispositivo ecg
JP1719683S (ja) 電気コネクタ
JP1719731S (ja) 電気コネクタ
MY155507A (en) Antiviral compounds
PH12016500226A1 (en) Electronic circuit connecting structure